| Sonstiges: |
- Nachgewiesen in: USPTO Patent Grants
- Sprachen: English
- Patent Number: 7,803,148
- Publication Date: September 28, 2010
- Appl. No: 11/759387
- Application Filed: June 07, 2007
- Assignees: NeuroSystec Corporation (Valencia, CA, US)
- Claim: 1. An apparatus, comprising: a drug reservoir configured for implantation in the body cavity of a living human and having a drug reservoir cavity, the drug reservoir cavity containing solid basic form gacyclidine not bound to a biodegradable polymer, the drug reservoir cavity configured to receive a substantially continuous flow of a fluid having an acid concentration corresponding to a desired gacyclidine dosage, the drug reservoir cavity further configured to output the substantially continuous flow of fluid entraining gacyclidine in the desired dosage; a catheter configured for implantation into the body cavity of a living human with the drug reservoir, the catheter including a lumen forming a conduit for the substantially continuous flow of fluid entraining gacyclidine in the desired dosage; and a terminal component coupled to the catheter and including at least one outlet in fluid communication with the catheter lumen, at least a portion of the terminal component including the outlet being configured for direct implantation into the inner ear tissue of a living human into the body cavity of which the drug reservoir and catheter have been implanted, and wherein the apparatus is configured to change the acid concentration, after initial placement of gacyclidine in the drug reservoir, without removal of gacyclidine from the drug reservoir, and without removal of the apparatus from the body cavity of the living human.
- Claim: 2. The apparatus of claim 1 , wherein the terminal component comprises a cochlear implant electrode.
- Claim: 3. The apparatus of claim 1 , further comprising a screen located in the drug reservoir cavity and positioned to prevent migration of the solid basic form gacyclidine from the drug reservoir cavity.
- Claim: 4. The apparatus of claim 1 , further comprising a pump configured for implantation into the body cavity of a living human with the drug reservoir and configured to propel the fluid past the solid basic form gacyclidine in the drug reservoir cavity.
- Claim: 5. The apparatus of claim 4 , wherein the pump is external to a housing for the drug reservoir.
- Claim: 6. The apparatus of claim 4 , wherein the pump and the drug reservoir are contained within the same housing.
- Claim: 7. The apparatus of claim 1 , wherein the drug reservoir is configured for non-destructive opening and fluid-tight reclosure so as to permit replenishment of the solid basic form gacyclidine.
- Claim: 8. The apparatus of claim 1 , comprising an electronics package and one or more electrodes configured to provide electrical stimulation to the middle or inner ear tissue.
- Claim: 9. The apparatus of claim 1 , further comprising an electronics package and one or more magnetic coils configured to produce a magnetic field so as to propel particles in the fluid that has flowed past the solid basic form gacyclidine.
- Claim: 10. The apparatus of claim 9 , wherein the particles are magnetic nanoparticles.
- Claim: 11. The apparatus of claim 1 , wherein the catheter comprises at least two fluid conduits, each of the fluid conduits having a first opening in fluid communication with the drug reservoir cavity and a second opening positionable remotely from the drug reservoir cavity, wherein the apparatus is configured to expel the fluid and entrained gacyclidine from one of the second openings and to receive the fluid through the other of said second openings.
- Claim: 12. The apparatus of claim 1 , further including a subcutaneously implantable port.
- Claim: 13. The apparatus of claim 12 , wherein the drug reservoir is part of the subcutaneously implantable port.
- Claim: 14. The apparatus of claim 1 , wherein the drug reservoir includes a semi-permeable membrane or one-way valve positioned to admit physiological fluid into the drug reservoir cavity.
- Claim: 15. The apparatus of claim 1 , further comprising an electronics package and one or more sensors configured to sense, as to vehicle and entrained drug from the solid basic form gacyclidine, one or more of the following: pH, absorbance of light, electrical conductivity, light scattering, drug concentration and electrolyte concentration.
- Claim: 16. The apparatus of claim 1 , further comprising an electronics package and one or more sensors configured to sense sound.
- Claim: 17. The apparatus of claim 1 , further comprising an electronics package and one or more sensors configured to sense tissue electrical activity.
- Claim: 18. The apparatus of claim 1 , further comprising a supply of a liquid vehicle, and wherein the apparatus is configured to utilize the liquid vehicle as the fluid.
- Claim: 19. The apparatus of claim 1 , wherein the terminal component comprises a needle configured for passage through bone.
- Claim: 20. The apparatus of claim 1 , wherein the solid basic form gacyclidine is unencapsulated and lacks a binder.
- Current U.S. Class: 604/416
- Patent References Cited: 3850161 November 1974 Liss ; 3881495 May 1975 Pannozzo et al. ; 4034756 July 1977 Higuchi et al. ; 4232679 November 1980 Schulman ; 4360019 November 1982 Portner et al. ; 4408608 October 1983 Daly et al. ; 4481950 November 1984 Duggan ; 4484921 November 1984 Swanson et al. ; 4487603 December 1984 Harris ; 4511355 April 1985 Franetzki et al. ; 4590946 May 1986 Loeb ; 4608985 September 1986 Crish et al. ; 4628942 December 1986 Sweeney et al. ; 4639244 January 1987 Rizk et al. ; 4649936 March 1987 Ungar et al. ; 4692147 September 1987 Duggan ; 4702254 October 1987 Zabara ; 4725852 February 1988 Gamblin et al. ; 4756710 July 1988 Bondi et al. ; 4819647 April 1989 Byers et al. ; 4929236 May 1990 Sampson ; 4944659 July 1990 Labbe et al. ; 5041107 August 1991 Heil, Jr. ; 5188104 February 1993 Wernicke et al. ; 5207640 May 1993 Hattler ; 5215086 June 1993 Terry, Jr. et al. ; 5299569 April 1994 Wernicke et al. ; 5305445 April 1994 Nishikawa ; 5305745 April 1994 Zacouto ; 5314458 May 1994 Najafi et al. ; 5330515 July 1994 Rutecki et al. ; 5354279 October 1994 Hofling ; 5358514 October 1994 Schulman et al. ; 5421818 June 1995 Arenberg ; 3894538 July 1995 Richter ; 5441481 August 1995 Mishra et al. ; 5468253 November 1995 Bezwada ; 5474529 December 1995 Arenberg ; 5476446 December 1995 Arenburg ; 5538735 July 1996 Ahn ; 5545152 August 1996 Funderburk et al. ; 5563140 October 1996 Ehrenberger et al. ; 5643207 July 1997 Rise ; 5690652 November 1997 Wurster et al. ; 5700282 December 1997 Zabara ; 5707361 January 1998 Slettenmark ; 5716318 February 1998 Manning ; 5728396 March 1998 Peery et al. ; 5752979 May 1998 Benabid ; 5755750 May 1998 Petruska et al. ; 5836935 November 1998 Ashton et al. ; 5849015 December 1998 Haywood et al. ; 5863927 January 1999 Smith et al. ; 5865789 February 1999 Hattler ; 5895372 April 1999 Zenner et al. ; 5895416 April 1999 Barreras et al. ; 5945052 August 1999 Schryver et al. ; 5971953 October 1999 Bachynsky ; 5980928 November 1999 Terry ; 5985305 November 1999 Peery et al. ; 5995868 November 1999 Dorfmeister et al. ; 6013051 January 2000 Nelson ; 6045528 April 2000 Arenberg et al. ; 6066652 May 2000 Zenner et al. ; 6067474 May 2000 Schulman et al. ; 6104956 August 2000 Naritoku et al. ; 6112116 August 2000 Fichell et al. ; 6129753 October 2000 Kuzma ; 6178349 January 2001 Kieval ; 6181969 January 2001 Gord ; 6205359 March 2001 Boveja ; 6219580 April 2001 Faltys et al. ; 6266564 July 2001 Hill et al. ; 6309410 October 2001 Kuzma et al. ; 6341236 January 2002 Osorio et al. ; 6377849 April 2002 Lenarz et al. ; 6393325 May 2002 Mann et al. ; 6409698 June 2002 Robinson et al. ; 6436405 August 2002 Bakaletz et al. ; 6440102 August 2002 Arenberg et al. ; 6450984 September 2002 Lynch et al. ; 6458118 October 2002 Lent et al. ; 6464687 October 2002 Ishikawa et al. ; 6526318 February 2003 Ansarinia ; 6560490 May 2003 Grill et al. ; 6568910 May 2003 Parce ; 6585703 July 2003 Kassel et al. ; 6596752 July 2003 Lobl et al. ; 6597954 July 2003 Pless et al. ; 6613026 September 2003 Palasis et al. ; 6627246 September 2003 Mehta et al. ; 6648873 November 2003 Arenberg et al. ; 6656172 December 2003 Hildebrand ; 6670321 December 2003 Adamis ; 6685697 February 2004 Arenberg et al. ; 6692481 February 2004 Guerrero ; 6712753 March 2004 Manne ; 6718209 April 2004 Williamson et al. ; 6726678 April 2004 Nelson et al. ; 6743204 June 2004 Christenson et al. ; 6766817 July 2004 da Silva ; 6782292 August 2004 Whitehurst ; 6796957 September 2004 Carpenter et al. ; 6826428 November 2004 Chen et al. ; 6827559 December 2004 Peters et al. ; 6858220 February 2005 Greenberg et al. ; 6894456 May 2005 Tsukamoto et al. ; 6907295 June 2005 Gross et al. ; 6918404 July 2005 Dias da Silva ; 6928320 August 2005 King ; 6962580 November 2005 Adams et al. ; 7060284 June 2006 Kaumaya et al. ; 7066586 June 2006 da Silva ; 7079903 July 2006 O'Brien ; 7181287 February 2007 Greenberg ; 7200504 April 2007 Fister ; 7203548 April 2007 Whitehurst et al. ; 7242985 July 2007 Fridman et al. ; 7272449 September 2007 Dadd et al. ; 7277760 October 2007 Litvak et al. ; 7285255 October 2007 Kadlec et al. ; 7292890 November 2007 Whitehurst et al. ; 7297130 November 2007 Bergheim et al. ; 7308303 December 2007 Whitehurst et al. ; 7347854 March 2008 Shelton et al. ; 2001/0003799 June 2001 Boveja ; 2001/0041870 November 2001 Gillis et al. ; 2002/0016615 February 2002 Dev et al. ; 2002/0022873 February 2002 Erickson et al. ; 2002/0095133 July 2002 Gillis et al. ; 2002/0182186 December 2002 Loeb ; 2002/0183722 December 2002 Harper et al. ; 2002/0188282 December 2002 Greenberg ; 2003/0083698 May 2003 Whitehurst et al. ; 2003/0097121 May 2003 Jolly et al. ; 2003/0114830 June 2003 Guerrero ; 2003/0171738 September 2003 Konieczynski et al. ; 2003/0203890 October 2003 Steiner et al. ; 2003/0236557 December 2003 Whitehurst et al. ; 2003/0236558 December 2003 Whitehurst et al. ; 2004/0015204 January 2004 Whitehurst et al. ; 2004/0015205 January 2004 Whitehurst et al. ; 2004/0043052 March 2004 Hunter et al. ; 2004/0044389 March 2004 Crawford ; 2004/0049175 March 2004 Speck et al. ; 2004/0091995 May 2004 Schlom et al. ; 2004/0105888 June 2004 Pratt et al. ; 2004/0141925 July 2004 Bosch et al. ; 2004/0156858 August 2004 Franzusoff et al. ; 2004/0172005 September 2004 Arenberg et al. ; 2004/0172089 September 2004 Whitehurst et al. ; 2004/0209836 October 2004 Spencer et al. ; 2004/0223949 November 2004 Astsaturov et al. ; 2004/0243182 December 2004 Cohen et al. ; 2004/0267238 December 2004 Haarala et al. ; 2005/0013812 January 2005 Dow et al. ; 2005/0049578 March 2005 Tu et al. ; 2005/0085778 April 2005 Parks ; 2005/0101878 May 2005 Daly et al. ; 2005/0119636 June 2005 Haffner et al. ; 2005/0130904 June 2005 Schloss ; 2005/0130920 June 2005 Simard et al. ; 2005/0137651 June 2005 Litvak et al. ; 2005/0184004 August 2005 Rodgers et al. ; 2005/0233964 October 2005 Kaumaya et al. ; 2005/0238506 October 2005 Mescher et al. ; 2005/0245906 November 2005 Makower et al. ; 2005/0245971 November 2005 Brockway et al. ; 2005/0256560 November 2005 Lenarz ; 2005/0267422 December 2005 Kriesel ; 2005/0277912 December 2005 John ; 2006/0009805 January 2006 Jensen et al. ; 2006/0030837 February 2006 McKenna et al. ; 2006/0041182 February 2006 Forbes et al. ; 2006/0047270 March 2006 Shelton ; 2006/0063802 March 2006 Guitton et al. ; 2006/0100672 May 2006 Litvak ; 2006/0106446 May 2006 Fridman et al. ; 2006/0177495 August 2006 Allen et al. ; 2006/0205789 September 2006 Lobl et al. ; 2006/0229688 October 2006 McClure et al. ; 2006/0264897 November 2006 Lobl et al. ; 2007/0005308 January 2007 Lee et al. ; 2007/0021800 January 2007 Whitehurst et al. ; 2007/0088335 April 2007 Jolly ; 2007/0123938 May 2007 Haller et al. ; 2007/0255237 November 2007 Lobl et al. ; 2007/0260292 November 2007 Faltys et al. ; 2008/0009836 January 2008 Fiering et al. ; 2008/0033520 February 2008 Jolly ; 2008/0065002 March 2008 Lobl et al. ; 2008/0145439 June 2008 Lobl et al. ; 343910 November 1989 ; 9727840 August 1997 ; 9917819 April 1999 ; 0004854 February 2000 ; 2003072193 September 2003 ; 03099351 December 2003 ; 2004022069 March 2004 ; 2005072793 August 2005 ; 2006053101 May 2006 ; 2007030496 March 2007
- Other References: Gaviria, M. et al. Brain Research. vol. 874, Iss. 2, Aug. 25, 2000, p. 200-209. “Neuroprotective Effects of a Novel NMDA Antagonist, Gacyclidine, After Experimental Contusive Spinal Cord Injury in Adult Rats.” cited by examiner ; András Hermann, et al., “Interference of S-Nitrosoglutathione with the Binding of Ligands to Ionotropic Glutamate Receptors in Pig Cerebral Cortical Synaptic Membranes,” Neurochemical Research, vol. 25, No. 8, 2000, pp. 1119-1124. cited by other ; C.P. Taylor, “Mechanisms of Action of Gabapentin”, Rev Neurol (Paris), 1997; 153 Suppl. 1:S39-45. cited by other ; Piotr Popik, et al., “The Putative Anti-Addictive Drug Ibogaine is a Competitive Inhibitor of [3H]MK-801 Binding to the NMDA Receptor Complex”, Psychoparmacology (1994) 114: 672-674. cited by other ; Mark J. Ginski, et al., “Sensitive and Rapid Behavioral Differentiation of N-methyl-D-aspartate Receptor Antagonists”, Psychopharmacology (1994) 114:573-582. cited by other ; Karin Agerman, et al., “Neurotrophins, NMDA Receptors, and Nitric Oxide in Development and Protection of the Auditory System”, Annals New York Academy of Sciences, Nov. 28, 1999, 884:131-142. cited by other ; Anthony S. Basile, et al., “N-Methyl-D-aspartate Antagonists Limit Aminoglycoside Antiobiotic-Induced Hearing Loss”, Nature Medicine, vol. 2, No. 12, Dec. 1996, pp. 1338-1343. cited by other ; Zhiqiang Chen, et al., “Acute Treatment of Noise Trauma with Local Caroverine Application in the Guinea Pig”, Acta Otolaryngol, Oct. 2003; 123(8):905-909. cited by other ; Zhiqiang Chen, et al., “Protection of Auditory Function Against Noise Trauma with Local Caroverine Administration in Guinea Pigs”, Hearing Research 197 (1-2), 2004, pp. 131-136. cited by other ; E. Costa, “From GABAA Receptor Diversity Emerges a Unified Vision of GABAergic Inhibition”, Annu. Rev. Pharmacol. Toxicol. 1998, 38:321-50. cited by other ; Maoli Duan, et al., “Complementary Roles of Neurotrophin 3 and a N-methyl-D-aspartate Antagonist in the Protection of noise and Aminoglycoside-induced Ototoxicity”, PNAS, Jun. 20, 2000, vol. 97, No. 13, pp. 7597-7602. cited by other ; Sophie Feldblum, et al., “Efficacy of a New Neuroprotective Agent, Gacyclidine, in a Model of Rat Spinal Cord Injury”, Journal of Neurotrauma, vol. 17, No. 11, 2000, pp. 1079-1093. cited by other ; Frauke Fischer, et al., “List of Drugs in Development for Neurodegenerative Diseases”, Neurodegenerative Dis 2004; 1:50-70. cited by other ; Ruggero Galici, et al., “Tolerance to and Dependence on Alprazolam are Due to Changes in GABAA Receptor Function and are Independent of Exposure to Experimental Set-up”, Restorative Neurology and Neuroscience 12 (1998); pp. 233-237. cited by other ; Michael J. Gallagher, et al., “Interactions Between Ifenprodil and the NR2B Subunit of the N-Methyl-D-aspartate Receptor”, The Journal of Biological Chemistry, vol. 271, No. 16, Issue of Apr. 19, 1996, pp. 9603-9611. cited by other ; Matthieu J. Guitton, et al., “New Pharmacological Strategies to Restore Hearing and treat Tinnitus”, Acta Otolaryngol, 2004; 124: 411-415. cited by other ; Greta Ann Herin, et al., “The Neuroprotective Agent Ebselen Modifies NMDA Receptor Function via the Redox Modulatory Site”, Journal fo neurochemistry, 2001, 78, 1307-1314. cited by other ; B.K. K Kohl, et al. “The NMDA Receptor Complex: A Promising Target for Novel Antiepileptic Strategies”, Current Medicinal Chemistry, Sep. 2001, 8, 1275-1289. cited by other ; Richard D. Kopke, et al., “Enhancing Intrinsic Cochlear Stress Defenses to Reduce Noise-Induced Hearing Loss”, The Laryngoscope 112: Sep. 2002, pp. 1515-1532. cited by other ; David B. Moody, “Animal Models of Tinnitus”, Tinnitus: Theory and Management, Chapter 7, pp. 80-95 (2004). cited by other ; Alan L. Mueller, et al., “NPS 1506, A Novel NMDA Receptor Antagonist and Neuroprotectant, Review of Preclinical and Clinical Studies”, Annals New York Academy of Sciences, 1999; 890:450-457. cited by other ; M. Nankai, et al., “NMDA Receptor Subtype Selectivity: Eliprodil, Polyamine Spider Toxins, Dextromethorphan, and Desipramine Selectively Block NMDA-Evoked Striatal Acetylcholine but Not Spermidine Release”, Journal of Neurochemistry, May 1995; 64(5): pp. 2043-2048. cited by other ; Nagendra S. Ningaraj, et al., “S-Methyl-N, N-Diethylthiocarbamate Sulfoxide Elicits Neuroprotective Effect against N-Methyl-D-Aspartate Receptor-Mediated Neurotoxicity”, Journal of Biomedical Science 2001; 8:104-113. cited by other ; Dominik Oliver, et al., “Memantine Inhibits Efferent Cholinergic Transmission in the Cochlea by Blocking Nicotinic Acetylcholine Receptors of Outer Hair Cells”, Molecular Pharmacology, vol. 60, No. 1, Jul. 2001; 60(1):183-189. cited by other ; Wojciech Danysz, et al., “Glycine and N-Methyl-D-Aspartate Receptors: Physiological Significance and Possible Therapeutic Applications”, Pharmacological Reviews, vol. 50, No. 4, pp. 597-664 (1998). cited by other ; Gene C. Palmer, “Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies”, Current Drug Targets, Sep. 2001, 2(3):241-71. cited by other ; Rémy Pujol, et al., “Excitotoxicity, Synaptic Repair, and Functional Recovery in the Mammalian Cochlea: A Review of Recent Findings”, Annals of the New York Academy of Sciences, 1999, 884: 249-254. cited by other ; Masahiro Sugimoto, et al., Local Anaesthetics Have Different Mechanisms and Sites of Action at the Recombinant N-methyl-D-aspartate (NMDA) Receptors), British Journal of Pharmacology (2003) 138, 876-882. cited by other ; Stephen M. Stahl, “Anticonvulsants and the Relief of Chronic Pain: Pregabalin and Gabapentin as alpha-2-delta Ligands at Voltage-Gated Calcium Channels”, J. Clin. Psychiatry 65:5, May 2004, pp. 596-597. cited by other ; Li-Ming Zhou, et al., “Synthetic Analogues of Conantokin-G: NMDA Antagonists Acting Through a Novel Polyamine-Coupled Site”, Journal of Neurochemistry, Feb. 1996, 66(2): 620-8. cited by other ; David R. Lynch, et al., “Pharmacological Characterization of Interactions of RO 25/6981 with the NR2B ( 2) Subunit”, European Journal of Pharmacology 416 (2001): 185-195. cited by other ; David R. Lynch, et al., “Inhibition of N-Methyl-D-Aspartate Receptors by Haloperidol: Developmental and Pharmacological Characterization in Native and Recombinant Receptors1”, The Journal of Pharmacology and Experimental Therapeutics, vol. 279, No. 1, Oct. 1996:154-61. cited by other ; Matthieu J. Guitton, et al., “New Pharmacological Strategies to Restore Hearing and Treat Tinnitus”, Acta Otolaryngol 2004; 124:411-415. cited by other ; Barbara A. Goldstein, et al., “Tinnitus Outcome Profile and Tinnitus Control”, International Tinnitus Journal, vol. 9, No. 1, 2003: 26-31. cited by other ; Doris-Maria Denk, et al., “Caroverine in Tinnitus Treatment”, Acta Otolaryngol (Stockh) 1997; 117:825-830. cited by other ; M.B. Hesselink, et al., “Modifications of the Behavioral Profile of Non-Competitive NMDA Receptor Antagonists, memantine, amantadine and (+)MK-801 after Chronic Administration”, Behavioural Pharmacology 1999; 10:85-98. cited by other ; Wojciech Danysz, et al., “Neuroprotective Potential of Ionotropic glutamate Receptor Antagonists”, Neurotoxicity Research, 2002, vol. 4(2), pp. 119-126. cited by other ; T. Oma Hester, et al., “Cyclandelate in the Management of Tinnitus: A Randomized, Placebo-Controlled Study”, Otolaryngol Head neck Surg., Mar. 1998, 118(3, Pt. 1): 329-332. cited by other ; Jan H. Hulshof, et al., “The Value of Tocainide in the Treatment of Tinnitus, A Double-Blind Controlled Study”, Arch Otorhinolaryngol (1985) 241:279-283. cited by other ; Th. Lenarz, “Treatment of Tinnitus with Lidocaine and Tocainide”, Scand. Audiol. Suppl., 1986: 26:49-51. cited by other ; Leif Nordang, et al., “Glutamate is the Afferent Neurotransmitter in the Human Cochlea”, Acta Otolaryngol 2000; 120:359-362. cited by other ; Elmar Oestreicher, et al., “Memantine Suppresses theGlutamatergic Neurotransmission of Mammalian Inner Hair Cells”, ORL J. Otorhinolaryngol Relat. Spec., Jan.-Feb. 1998; 60(1):18-21. cited by other ; Elmar Oestreicher, et al., “New Approaches for Inner Ear Therapy with Glutamate Antagonists”, Acta Otolaryngol, Mar. 1999; 119(2):174-178. cited by other ; Elmar Oestreicher, et al., “Different Action of Memantine and Caroverine on Glutamatergic Transmission in the Mammalian Cochlea”, Adv. Otorhinolaryngol, 2002; 59:18-25. cited by other ; E. Perucca, et al., A Controlled Study of the Suppression of Tinnitus by Lidocaine Infusion: (Relationship of Therapeutic Effect with Serum Lidocaine Levels); The Journal of Laryngology and Otology, Jul. 1985, vol. 99, pp. 657-661. cited by other ; Michael D. Seidman, et al., “Pharmacologic Manipulation of the Labyrinth with Novel and Traditional Agents Delivered to the Inner Ear”, ENT-Ear, Nose & Throat Journal, Apr. 2003; 82(4); 276-280, 282-283, 287-288. cited by other ; Wojciech Danysz, et al., “Glutamate Antagonists Have Different Effects on Spontaneous Locomotor Activity in Rats”, Pharmacology Biochemistry and Behavior, 1994, vol. 48, No. 1, pp. 111-118. cited by other ; Chrysanthy Ikonomidou, et al., “Why did NMDA Receptor Antagonists Fail Clinical Trials for Stroke and Traumatic Brain Injury?”, The Lancet neurology, vol. 1(6), Oct. 2002: 383-386. cited by other ; T. Lenarz, et al., “Tinnitus Therapy with Liodcaine and Tocainide”, Laryngol Rhinol. Otol (Stuttg.); Dec. 1985, 64 (12):604-608 (with English Abstract). cited by other ; K. Ogita, et al., “Nitric Oxide-Independent Inhibition by Sodium Nitroprusside of the Native N-methyl-D-aspartate Recognition Domain in a Manner Different from that by Potassium Ferrocyanide”, Neurochem. Int. 33 (1998):1-9. cited by other ; Steven L. Peterson, et al., “Differential Neuroprotective Effects of the NMDA Receptor-Associated Glycine Site Partial Agonists 1-Aminocyclopropanecarboxylic Acid (ACPC) and D-Cycloserine in Lithium-Pilocarpine Status Epilepticus”, NeuroToxicology 25 (2004):835-847. cited by other ; Margaret A. Petty, et al., “ACEA 1021: Flip or Flop?”, CNS Drive Reviews, vol. 10, No. 4, pp. 337-348 (2004). cited by other ; Jacob B. Schwarz, et al., “Novel Cyclopropyl B-Amino Acid Analogues of Pregabalin and gabapentin that Target the alpha-2-delta Protein”, J. Med. Chem. 2005, 48, pp. 2026-3035. cited by other ; Stanislaw J. Czuczwar, et al., “The New Generation of GABA Enhancers, Potential in the Treatment of Epilepsy”, CNS Drugs, 2001; 15(5):339-350. cited by other ; David J. Hewitt, et al., “The Use of NMDA-Receptor Antagonists in the Treatment of Chronic Pain”, The Clinical Journal ofPain, Jun. 2000; 16(2 Suppl.):S73-79. cited by other ; Sveta Mayer, et al., “Acamprosate, MK-801, and Ifenprodil Inhibit Neurotoxicity and Calcium Entry Induced by Ethanol Withdrawal in Organotypic Slice Cultures from Neonatal Rat Hippocampus”, Alcohol Clin. Exp. Res., Oct. 2002; 26 (10):1468-78. cited by other ; Zhang-Lin Zhou, et al., “4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: A Novel, Potent, and Selective NR1/2B NMDA Receptor Antagonist”, J. Med. Chem. 1999, 42, 2993-3000. cited by other ; Richard K. Gordon, et al., “The NMDA Receptor Ion Channel: a Site for Binding of Huperzine A”, Journal of Applied Toxicology, 2001;21:S47-S51. cited by other ; C.G. Parsons, et al., Comparison of the Potency, Kinetics and Voltage-Dependency of a Series of UnCompetitive NMDA Receptor Antagonists In Vitro with Anticonvulsive and Motor Impairment Activity In Vitro, Neuropharmacology, 1995; vol. 34, No. 10, pp. 1239-1258. cited by other ; U.S. Appl. No. 60/665,171, filed Mar. 24, 2005. cited by other ; Naveen K. Dakappagari, et al., “A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses1”, The Journal of Immunology, 170:4242-4253 (2003). cited by other ; Pravin T.P. Kaumaya, et al., “Design and Immunological Properties of Topographic Immunogenic Determinants of a Protein Antigen (LDH-C4) as Vaccines”, The Journal of Biological Chemistry, vol. 267, No. 9, Mar. 25, 1992, pp. 6338-6346. cited by other ; Susan Kobs-Conrad, et al., Engineered Topographic Determinants with alpha-beta, beta-alpha-beta, beta-alpha-beta-alpha and Topologies Show High Affinity Binding to Native Protein Antigen (Lactate Dehydrogenase-C4), The Journal of Biological Chemistry, vol. 268, No. 34, Dec. 5, 1993, pp. 25285-25295. cited by other ; Paolo Calabresi, et al., “Ionotropic Glutamate Receptors: Still a Target for Neuroprotection in Brain Ischemia? Insights from In Vitro Studies”, Neurobiology of Disease, 12 (2003): pp. 82-88. cited by other ; International Search Report from PCT/US07/09753 dated Dec. 26, 2007. cited by other ; International Search Report and Written Opinion from PCT/US06/02403 dated Dec. 4, 2007. cited by other ; Lautermann, J., “Glautathione-Dependent Antioxidant Systems in the Mammalian Inner Ear: Effects of Aging, Ototoxic Drugs and Noise”, Hear Res., Dec. 1997, 114 (1-2) p. 75, Abstract. cited by other ; U.S. Appl. No. 11/780,853, filed Jul. 20, 2007. cited by other ; U.S. Appl. No. 11/831,230, filed Jul. 31, 2007. cited by other ; Konishi, T., et al. (1973), “Effect of Potassium Deficiency on Cochlear Potentials and Cation Contents of the Endolymph”, Acta Otolaryng 76:410-8. cited by other ; Feng, B., et al., (2004), “Structure-Activity Analysis of a Novel NR2C/NR2D-Preferring NMDA Receptor Antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid”, Br. J. Pharmacol. 141:508-516. cited by other ; Geneste P., et al. (1979) “Détermination conformationnelle de dérivés de la phenycyclidine en vue d'une corrélation structure-activité”, Eur. J. Med Chem. 14:301-308. cited by other ; Hansen, R.E., et al., (1988) “Determination of the Regime of Rapid Reacting Systems in Stopped- and Steady-flow Investigations by the Velocity Probe Method”, J. Phys. Chem. 92:2189-2196. cited by other ; Lu Y, et al. (2004) “Micro and Nano-Fabrication of Biodegradable Polymers for Drug Delivery”, Adv. Drug Deliv. Rev. 56:1621-1633. cited by other ; Morris A.W., et al. (1989), “Cochlear Dialysis for Meniere's Disease”, An Update. Am J. Otol. 10:148-9. cited by other ; Muly S.M., et al. (2004) “Noise Trauma Alters D-[3H]aspartate Release and AMPA Binding in Chinchilla Conchlear Nucleus”, J. Neurosci. Res. 75:585-596. cited by other ; Orive G., et al., (2005) “Micro and Nano Drug Delivery Systems in Cancer Therapy”, Cancer Therapy 3:131-138. cited by other ; Prakobvaitayakit M., et al. (2003) “Optimization of polylactic-co-glycolic Acid Nanoparticles Containing Itraconizole Using 23 Factorial Design”, AAPS PharmaSciTech 4(4):Article 71 (http://www.aapspharmascitech.org). cited by other ; Takizawa S., et al. (1995), “A Selective N-type Calcium Channel Antagonist Reduces Extracellular Glutamate Release and Infarct volume in Focal Cerebral Ischemia”, J. Cerebral Blood Flow Metab. 15:611-8. cited by other ; Mizukoshi, et al., “Drug Delivery to the Cochlea Using Poly Lactic/glycolic Acid Nanoparticles”, Abstracts of the Twenty-Ninth Annual Midwinter Research Meeting, Feb. 5-9, 2006, ARO Abstracts, vol. 29, 2006, 5 pages. cited by other ; Sun, et al., “Neurotrophin-3 Gene Transfection of Cochlear Cells with hydroxyapatite Nanoparticle Vector”, Abstracts of the Twenty-Ninth Annual Midwinter Research Meeting, Feb. 5-9, 2006, ARO Abstracts, vol. 29, 2006, 5 pages. cited by other ; Pedrini, et al., “Evaluation of Thrombogenicity of Fluoropassivated Polyester Patches Following Carotid Endarterectomy”, Nov. 2001 Ann. Vasc. Surg. 15(6):679-83. cited by other ; Kim, et al., “An Experimental Study on Thrombogenicity of Various Metallic Microcoils with or without Thrombogenic Coatings” Jul. 1998, Invest. Radiol. 33(7):407-410. cited by other ; Hong, et al., “Material-Specific Thrombin Generation Following Contact Between Metal Surfaces and Whole Blood”, Apr. 2005, Biomaterials 26(12):1397-403. cited by other ; Salt A.N., et al., (1998) “Longitudinal Endolymph Movements Induced by Perilymphatic Injections”, Hearing Research 123:137-147. cited by other ; Feijen R.A., et al., (Mar. 1, 2002) “Change of Guinea Pig Inner Ear Pressure by Square Wave Middle Ear Cavity Pressure Variation”, Acta Otolaryngologica, 122:No. 2:138-45. cited by other ; Sennaroglu L., et al., (Sep. 2001) “Relationship of Vestibular Aqueduct and Inner Ear Pressure in Meniere's Disease and the Normal Population”, Laryngoscope 111:1625-1630. cited by other ; Salt An, et al., (2003), “Contamination of Perilymph Sampled from the Basal Cochlear Turn with Cerebrospinal Fluid”, Hearing Research 182:24-33. cited by other ; U.S. Appl. No. 61/022,224, filed Jan. 18, 2008. cited by other ; Rodrigues CM, et al., (2003), “Tauroursodeoxycholic Acid Reduces Apoptosis and Protects Against Neurological Injury After Acute Hemorrhagic Stroke in Rats”, Proc Natl Acad Sci USA 100:6087-6092. cited by other ; Unsolicited email, purporting to be from Elson Silva, received May 4, 2008 by Applicants' representative. cited by other ; U.S. Appl. No. 11/008,869, filed Dec. 9, 2004. cited by other ; U.S. Appl. No. 11/016,604, filed Dec. 16, 2004. cited by other ; U.S. Appl. No. 11/089,171, filed Mar. 24, 2005. cited by other ; U.S. Appl. No. 11/122,648, filed May 5, 2005. cited by other ; U.S. Appl. No. 11/139,296, filed May 26, 2005. cited by other ; U.S. Appl. No. 11/178,054, filed Jul. 8, 2005. cited by other ; U.S. Appl. No. 11/226,777, filed Sep. 13, 2005. cited by other ; U.S. Appl. No. 11/261,432, filed Oct. 28, 2005. cited by other ; U.S. Appl. No. 11/262,055, filed Oct. 28, 2005. cited by other ; U.S. Appl. No. 11/386,198, filed Mar. 21, 2006. cited by other ; International Search Report and Written Opinion for PCT/US07/13686 dated Jul. 23, 2008. cited by other ; International Search Report and Written Opinion for PCT/US07/19385 dated Jul. 28, 2008. cited by other ; International Search Report and Written Opinion for PCT/US07/16414 dated Aug. 12, 2008. cited by other ; Hoizey, et al., “Distribution of Gacyclidine Enantiomers after Experimental Spinal Cord Injury in Rats”, J. of Pharm. Sci., vol. 90, No. 1, pp. 70-78. cited by other ; International Search Report and Written Opinion for PCT/US07/17109 dated Aug. 22, 2008. cited by other ; International Preliminary Report on Patentability for PCT/US2007/009753 dated Nov. 4, 2008. cited by other ; International Preliminary Report on Patentability for PCT/US2007/013686 dated Dec. 10, 2008. cited by other ; Office action mailed Dec. 22, 2008 in U.S. Appl. No. 11/831,230. cited by other ; Gould, et al., International Journal of Pharmaceutics, 33 (1986), pp. 201-217. cited by other ; Hirbec, et al., “Gacyclidine: A New Neuroprotective Agent Acting at the N-Methyl-D-Aspartate Receptor”, CNS Drug Reviews, vol. 7, No. 2, pp. 172-198, 2001. cited by other ; Supplementary European Search Report for EP07755859 dated Jun. 9, 2010. cited by other
- Assistant Examiner: Marcetich, Adam
- Primary Examiner: Zalukaeva, Tatyana
- Attorney, Agent or Firm: Banner & Witcoff, Ltd.
|
